Navigation Links
China Medical Technologies Announces the Use of its HER-2 FISH Probe in a Cancer Targeted Therapy Research Project Sponsored by the Chinese Ministry of Health

BEIJING, July 15 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc. (the "Company") (Nasdaq: CMED), a leading China-based advanced in-vitro diagnostic ("IVD") company, today announced that its HER-2 FISH probe has been chosen to be used in a research project focusing on cancer targeted therapy standardization, as well as early cancer detection and treatment, which is sponsored by the Chinese Ministry of Health. One of the subjects of this research project is to standardize the process and procedures for the use of FISH technology to detect HER-2 gene amplification in breast cancer and stomach cancer patients to guide the use of Herceptin (the "HER-2 Study"). The Company is the supplier of HER-2 FISH probe for the HER-2 Study.

Immunohistochemistry used to be the traditional diagnostic method in detecting HER-2 gene amplification in China, but it has false positive and false negative results. The HER-2 Study is the first study in China to include FISH technology as the gold standard in HER-2 gene amplification detection. The Company believes that the results of the HER-2 Study may contribute to more widespread use of its HER-2 FISH probe in the companion diagnostic test market in China for guiding treatment for breast cancer and stomach cancer. According to the Chinese Central Government's Official Web Portal, about 200,000 new cases of breast cancer and 400,000 new cases of stomach cancer are diagnosed in China each year.

"We believe that our selection as the supplier of HER-2 FISH probe in the HER-2 Study by the top ranking cancer research institute demonstrates the good quality of our HER-2 FISH probe," commented Mr. Xiaodong Wu, Chairman and Chief Executive Officer of the Company.

The HER-2 Study is led by the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences with Dr. Yuankai Shi as the principal investigator.

About China Medical Technologies, Inc.

China Medical Technologies, Inc. is a leading China-based advanced IVD company using molecular diagnostic technologies including Fluorescent in situ Hybridization (FISH) and Surface Plasmon Resonance (SPR) and an immunodiagnostic technology, Enhanced Chemiluminescence Immunoassay (ECLIA), to develop, manufacture and distribute diagnostic products used for the detection of various cancers, diseases and disorders as well as companion diagnostic tests for targeted cancer drugs. The Company generates all of its revenues in China through the sale of diagnostic consumables including FISH probes, SPR-based DNA chips and ECLIA reagent kits to hospitals which are recurring users of the consumables for their patients. The Company sells FISH probes and SPR chips to large hospitals through its direct sales force and ECLIA reagent kits to small and mid-size hospitals through distributors. For more information, please visit .

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Such statements involve certain risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, including the risk that the results of the HER-2 Study will not lead to increased use of the Company's HER-2 FISH probe. Further information regarding these and other risks is included in the Company's filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

    For more information, please contact:

     Winnie Yam
     Phone: +852-2511-9808

SOURCE China Medical Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MarketsandMarkets: Patient Monitoring Devices Markets in Brazil, Russia, India and China Worth $2,992 Million by 2015
2. Renhuang Showcases its All Natural Products at 45th China National New and Special Drugs Fair
3. China Medicine Announces Stock Repurchase Plan
4. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
5. New Report Patient Monitoring Emerging Markets (BRIC - Brazil, Russia, India and China) 2010 - 2014 Published by MarketsandMarkets
6. China-Biotics, Inc. Announces US$20 million Share Buyback Program
7. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
8. Weikang Bio-Technology to Present at Global Hunter 2010 China Conference on July 13, 2010
9. China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2010 on August 16, 2010
10. Samplify Expands Global Presence; Opens China Office
11. China PharmaHub Corp. Enters Into Definitive Agreement for Humanized Antibody
Post Your Comments:
(Date:12/1/2015)... , Dec. 1, 2015  The migration ... to develop shared care plans that help patients ... care plans will be digitally enabled, incorporate care ... needs and desires. They will also allow all ... patient,s health journey is optimal. That is the ...
(Date:12/1/2015)... , December 1, 2015 ... of eye and gaze tracking solutions, today announced that ... trackers as a component of its revolutionary new vision ... and medical and performance issues in patients. The new ... mass-market-ready eye tracking platform, which is ready to be ...
(Date:12/1/2015)... Dec. 1, 2015  Lexicon Pharmaceuticals, Inc. ... top-line data from its TELECAST Phase 3 ... treating carcinoid syndrome in cancer patients with ... benefit observed in its pivotal TELESTAR study.  ... companion to TELESTAR primarily to provide additional ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... December 01, 2015 , ... XTC Semifinals 2016 ... semi-finalists to head to Las Vegas for CES 2016, the world’s largest Consumer Electronic ... Consumer Technology Association Gary Shapiro, Founding Partner of Pacific Investments Veronica Serra, and venture ...
(Date:12/1/2015)... ... ... With FCPX Overlay: Grit , users can apply a grit effect ... truly endless, all with a click of a mouse. Each user has full control ... of field and more, all within Final Cut Pro X. , With FCPX Overlay: ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Magazine as a Modern Man for 2015. , Angeleno Magazine is a ... United States. Established in 1994, Modern Luxury includes more than 50 magazine titles ...
(Date:12/1/2015)... ... December 01, 2015 , ... ... Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani as ... Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center marketplace. ...
(Date:11/30/2015)... ... November 30, 2015 , ... Olympic Gold Medalists ... collaborating with brands across various categories through traditional and social media marketing campaigns ... elite group of Gold Medal Moms who can connect with today’s most important ...
Breaking Medicine News(10 mins):